[P16] Human Apolipoprotein E (Apo E)50P-1005
|Concentration:||0.9 mg / ml, determined by the Lowry method|
|Source:||From fresh human plasma that has tested negative for Hepatitis C, HIV-I and HIV-II antibodies as well as Hepatitis surface antigens.|
|Purification:||After series ultracentrifugations, Very Low density Lipoprotein (VLDL) is isolated from human plasma. Apo E is purified from delipidated VLDL, followed by gel-filtration. Minor impurities of other apo-proteins are then removed by antibody-Sepharose™ affinity column.|
|Purity:||≥ 98% by SDS-PAGE|
|Buffer:||20 mM Tris-HCl, 0.15 mM NaCl, 0.5 mM EDTA, 0.02 % NaN3, pH 7.4.|
|Storage:||-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.|
*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.
Apo E contains 299 amino acid residues. It is a 34-37 kDa glycosylated protein (Rall et al., 1983).
Apo E is involved with triglyceride, phospholipid, cholesteryl ester, and cholesterol transport in and out of cells and is a ligand for LDL receptors. Apo E has also been implicated in immune and nerve degeneration. It has been found to suppress lymphocyte proliferation. Late-onset familial and sporadic Alzheimer disease patients have been found to have a higher occurrence of one of the three common Apo E isoforms, Apo E4. The Apo E4 isoform has been detected in senile plaques and neurofibrillary tangles of Alzheimer disease patients. Apo E4 is associated with rapid chylomicron-remnant clearance and increased total cholesterol levels.
Rall, S C, K H Weisgraber, T L Innerarity, T P Bersot, R W Mahley, and C B Blum. "Identification of a New Structural Variant of Human Apolipoprotein E, E2(Lys146 Leads to Gln), in a Type III Hyperlipoproteinemic Subject with the E3/2 Phenotype." Journal of Clinical Investigation 72.4 (1983): 1288-297.
|[P16]||2016||Yassine, Hussein N.; Feng, Qingru; Chiang, Jiarong; Petrosspour, Larissa M.; Fonteh, Alfred N.; Chui, Helena C.; Harrington, Michael G. (2016): ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease. In Journal of the American Heart Association 5 (2). DOI: 10.1161/JAHA.115.002886.|
|[P16]||2014||O’Callaghan, Paul; Noborn, Fredrik; Sehlin, Dag; Li, Jin-ping; Lannfelt, Lars; Lindahl, Ulf; Zhang, Xiao (2014): Apolipoprotein E increases cell association of amyloid-β 40 through heparan sulfate and LRP1 dependent pathways. In Amyloid 21 (2), pp. 76–87. DOI: 10.3109/13506129.2013.879643.|
|[P16]||2009||Benyamini, Payam; Webster, Paul; Meyer, David I. (2009): Knockdown of p180 eliminates the terminal differentiation of a secretory cell line. In Molecular biology of the cell 20 (2), pp. 732–744. DOI: 10.1091/mbc.E08-07-0682.|
|[P16]||2006||Kawakami, Akio; Aikawa, Masanori; Libby, Peter; Alcaide, Pilar; Luscinskas, Francis W.; Sacks, Frank M. (2006): Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. In Circulation 113 (5), pp. 691–700. DOI: 10.1161/CIRCULATIONAHA.105.591743.|